Laurion Capital Management LP Buys New Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF)

Laurion Capital Management LP bought a new stake in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 576,924 shares of the company's stock, valued at approximately $2,504,000. Laurion Capital Management LP owned approximately 1.13% of Cardiff Oncology at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of CRDF. Bank of New York Mellon Corp increased its holdings in Cardiff Oncology by 68.7% in the fourth quarter. Bank of New York Mellon Corp now owns 288,615 shares of the company's stock valued at $1,253,000 after buying an additional 117,514 shares during the last quarter. HB Wealth Management LLC acquired a new position in shares of Cardiff Oncology during the 4th quarter worth about $105,000. American Century Companies Inc. increased its holdings in shares of Cardiff Oncology by 12.8% in the 4th quarter. American Century Companies Inc. now owns 53,955 shares of the company's stock valued at $234,000 after acquiring an additional 6,140 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Cardiff Oncology by 24.0% in the 4th quarter. Rhumbline Advisers now owns 53,172 shares of the company's stock valued at $231,000 after acquiring an additional 10,290 shares during the last quarter. Finally, Barclays PLC raised its position in shares of Cardiff Oncology by 291.9% during the 3rd quarter. Barclays PLC now owns 53,089 shares of the company's stock worth $141,000 after acquiring an additional 39,542 shares in the last quarter. 16.29% of the stock is currently owned by hedge funds and other institutional investors.

Cardiff Oncology Trading Up 3.0%

Shares of Cardiff Oncology stock traded up $0.08 on Thursday, hitting $2.75. The stock had a trading volume of 680,459 shares, compared to its average volume of 1,120,936. The stock has a market cap of $182.95 million, a price-to-earnings ratio of -2.93 and a beta of 1.81. Cardiff Oncology, Inc. has a 52-week low of $2.01 and a 52-week high of $5.64. The company's 50 day moving average price is $3.06 and its 200 day moving average price is $3.46.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The business had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.09 million. Cardiff Oncology had a negative return on equity of 73.97% and a negative net margin of 6,238.17%. Analysts predict that Cardiff Oncology, Inc. will post -0.99 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright increased their price target on shares of Cardiff Oncology from $17.00 to $18.00 and gave the company a "buy" rating in a research note on Friday, May 9th.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.